The pharmaceutical version (Zadaxin) is approved in 35+ countries with continuous dosing protocols
A retrospective study published in October of 2020 conducted in Changsha (China) analyzed clinical and laboratory data of 149 patients with mild COVID-19 infection within the first 3 months of the pandemic and detected that 28% had NTIS, characterized by fT 3 0.35 ng/mL) in 63% of the patients and were significantly higher in critical patients compared to non-critical patients
The reality check: the FDA does not consider it a legal cosmetic or dietary ingredient, and there is real concern that long-term use raises the risk of melanoma (skin cancer) the opposite of what most people assume a tan in a vial would do for skin safety (WebMD)
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ,
Aging (Albany NY) 13 (22), 2451124523